Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The 2019 PGDIS position statement on transfer of mosaic embryos within a context of new information on PGT-A

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Gleicher, N, Albertini, DF, Barad, DH, Homer, H, Modi, D, Murtinger, M, Patrizio, P, Orvieto, R, Takahashi, S, Weghofer, A, Ziebe, S, Noyes, N & International Do No Harm Group in IVF (IDNHG-IVF) 2020, 'The 2019 PGDIS position statement on transfer of mosaic embryos within a context of new information on PGT-A', Reproductive Biology and Endocrinology, bind 18, nr. 1, s. 57. https://doi.org/10.1186/s12958-020-00616-w

APA

Gleicher, N., Albertini, D. F., Barad, D. H., Homer, H., Modi, D., Murtinger, M., Patrizio, P., Orvieto, R., Takahashi, S., Weghofer, A., Ziebe, S., Noyes, N., & International Do No Harm Group in IVF (IDNHG-IVF) (2020). The 2019 PGDIS position statement on transfer of mosaic embryos within a context of new information on PGT-A. Reproductive Biology and Endocrinology, 18(1), 57. https://doi.org/10.1186/s12958-020-00616-w

CBE

Gleicher N, Albertini DF, Barad DH, Homer H, Modi D, Murtinger M, Patrizio P, Orvieto R, Takahashi S, Weghofer A, Ziebe S, Noyes N, International Do No Harm Group in IVF (IDNHG-IVF). 2020. The 2019 PGDIS position statement on transfer of mosaic embryos within a context of new information on PGT-A. Reproductive Biology and Endocrinology. 18(1):57. https://doi.org/10.1186/s12958-020-00616-w

MLA

Vancouver

Author

Gleicher, N ; Albertini, D F ; Barad, D H ; Homer, H ; Modi, D ; Murtinger, M ; Patrizio, P ; Orvieto, R ; Takahashi, S ; Weghofer, A ; Ziebe, S ; Noyes, N ; International Do No Harm Group in IVF (IDNHG-IVF). / The 2019 PGDIS position statement on transfer of mosaic embryos within a context of new information on PGT-A. I: Reproductive Biology and Endocrinology. 2020 ; Bind 18, Nr. 1. s. 57.

Bibtex

@article{d4c224d56ad842f4a5baa9a627a1ae7e,
title = "The 2019 PGDIS position statement on transfer of mosaic embryos within a context of new information on PGT-A",
abstract = "BACKGROUND: A recently published Position Statement (PS) by the Preimplantation Genetics Diagnosis International Society (PGDIS) regarding utilization of preimplantation genetic testing for aneuploidy (PGT-A) in association with in vitro fertilization (IVF) contained inaccuracies and misrepresentations. Because opinions issued by the PGDIS have since 2016 determined worldwide IVF practice, corrections appear of importance.METHODS: The International Do No Harm Group in IVF (IDNHG-IVF) is a spontaneously coalesced body of international investigators, concerned with increasing utilization of add-ons to IVF. It is responsible for the presented consensus statement, which as a final document was reached after review of the pertinent literature and again revised after the recent publication of the STAR trial and related commentaries.RESULTS: In contrast to the PGDIA-PS, we recommend restrictions to the increasing, and by IVF centers now often even mandated, utilization of PGT-A in IVF cycles. While PGT-A has been proposed as a tool for achieving enhanced singleton livebirth outcomes through embryo selection, continued false-positive rates and increasing evidence for embryonic self-correction downstream from the testing stage, has led IDNHG-IVF to conclude that currently available data are insufficient to impose overreaching recommendations for PGT-A utilization.DISCUSSION: Here presented consensus offers an alternative to the 2019 PGDIS position statement regarding utilization of preimplantation genetic testing for aneuploidy (PGT-A) in association with in vitro fertilization (IVF). Mindful of what appears to offer best outcomes for patients, and in full consideration of patient autonomy, here presented opinion is based on best available evidence, with the goal of improving safety and efficacy of IVF and minimizing wastage of embryos with potential for healthy births.CONCLUSIONS: As the PGDIS never suggested restrictions on clinical utilization of PGT-A in IVF, here presented rebuttal represents an act of self-regulation by parts of the IVF community in attempts to control increasing utilization of different unproven recent add-ons to IVF.",
author = "N Gleicher and Albertini, {D F} and Barad, {D H} and H Homer and D Modi and M Murtinger and P Patrizio and R Orvieto and S Takahashi and A Weghofer and S Ziebe and N Noyes and {International Do No Harm Group in IVF (IDNHG-IVF)}",
year = "2020",
month = may,
day = "29",
doi = "10.1186/s12958-020-00616-w",
language = "English",
volume = "18",
pages = "57",
journal = "Reproductive Biology and Endocrinology",
issn = "1477-7827",
publisher = "BioMed Central Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - The 2019 PGDIS position statement on transfer of mosaic embryos within a context of new information on PGT-A

AU - Gleicher, N

AU - Albertini, D F

AU - Barad, D H

AU - Homer, H

AU - Modi, D

AU - Murtinger, M

AU - Patrizio, P

AU - Orvieto, R

AU - Takahashi, S

AU - Weghofer, A

AU - Ziebe, S

AU - Noyes, N

AU - International Do No Harm Group in IVF (IDNHG-IVF)

PY - 2020/5/29

Y1 - 2020/5/29

N2 - BACKGROUND: A recently published Position Statement (PS) by the Preimplantation Genetics Diagnosis International Society (PGDIS) regarding utilization of preimplantation genetic testing for aneuploidy (PGT-A) in association with in vitro fertilization (IVF) contained inaccuracies and misrepresentations. Because opinions issued by the PGDIS have since 2016 determined worldwide IVF practice, corrections appear of importance.METHODS: The International Do No Harm Group in IVF (IDNHG-IVF) is a spontaneously coalesced body of international investigators, concerned with increasing utilization of add-ons to IVF. It is responsible for the presented consensus statement, which as a final document was reached after review of the pertinent literature and again revised after the recent publication of the STAR trial and related commentaries.RESULTS: In contrast to the PGDIA-PS, we recommend restrictions to the increasing, and by IVF centers now often even mandated, utilization of PGT-A in IVF cycles. While PGT-A has been proposed as a tool for achieving enhanced singleton livebirth outcomes through embryo selection, continued false-positive rates and increasing evidence for embryonic self-correction downstream from the testing stage, has led IDNHG-IVF to conclude that currently available data are insufficient to impose overreaching recommendations for PGT-A utilization.DISCUSSION: Here presented consensus offers an alternative to the 2019 PGDIS position statement regarding utilization of preimplantation genetic testing for aneuploidy (PGT-A) in association with in vitro fertilization (IVF). Mindful of what appears to offer best outcomes for patients, and in full consideration of patient autonomy, here presented opinion is based on best available evidence, with the goal of improving safety and efficacy of IVF and minimizing wastage of embryos with potential for healthy births.CONCLUSIONS: As the PGDIS never suggested restrictions on clinical utilization of PGT-A in IVF, here presented rebuttal represents an act of self-regulation by parts of the IVF community in attempts to control increasing utilization of different unproven recent add-ons to IVF.

AB - BACKGROUND: A recently published Position Statement (PS) by the Preimplantation Genetics Diagnosis International Society (PGDIS) regarding utilization of preimplantation genetic testing for aneuploidy (PGT-A) in association with in vitro fertilization (IVF) contained inaccuracies and misrepresentations. Because opinions issued by the PGDIS have since 2016 determined worldwide IVF practice, corrections appear of importance.METHODS: The International Do No Harm Group in IVF (IDNHG-IVF) is a spontaneously coalesced body of international investigators, concerned with increasing utilization of add-ons to IVF. It is responsible for the presented consensus statement, which as a final document was reached after review of the pertinent literature and again revised after the recent publication of the STAR trial and related commentaries.RESULTS: In contrast to the PGDIA-PS, we recommend restrictions to the increasing, and by IVF centers now often even mandated, utilization of PGT-A in IVF cycles. While PGT-A has been proposed as a tool for achieving enhanced singleton livebirth outcomes through embryo selection, continued false-positive rates and increasing evidence for embryonic self-correction downstream from the testing stage, has led IDNHG-IVF to conclude that currently available data are insufficient to impose overreaching recommendations for PGT-A utilization.DISCUSSION: Here presented consensus offers an alternative to the 2019 PGDIS position statement regarding utilization of preimplantation genetic testing for aneuploidy (PGT-A) in association with in vitro fertilization (IVF). Mindful of what appears to offer best outcomes for patients, and in full consideration of patient autonomy, here presented opinion is based on best available evidence, with the goal of improving safety and efficacy of IVF and minimizing wastage of embryos with potential for healthy births.CONCLUSIONS: As the PGDIS never suggested restrictions on clinical utilization of PGT-A in IVF, here presented rebuttal represents an act of self-regulation by parts of the IVF community in attempts to control increasing utilization of different unproven recent add-ons to IVF.

U2 - 10.1186/s12958-020-00616-w

DO - 10.1186/s12958-020-00616-w

M3 - Journal article

C2 - 32471441

VL - 18

SP - 57

JO - Reproductive Biology and Endocrinology

JF - Reproductive Biology and Endocrinology

SN - 1477-7827

IS - 1

ER -

ID: 62294606